StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for GYRE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $6.60 | $6.44 | -2.42% | 0.1M |
| 05-19 | $6.40 | $6.26 | -2.19% | 0.1M |
| 05-20 | $6.26 | $6.04 | -3.51% | 0.1M |
| 05-21 | $6.04 | $6.18 | +2.32% | 0.1M |
| 05-22 | $6.22 | $6.06 | -2.57% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $22.52M | $116.59M | $79.39M | $48.83M |
Operating Income | $-9.36M | $11.49M | $11.37M | $4.44M |
Net Income | $-9.86M | $9.88M | $11.20M | $1.58M |
EPS (Diluted) | $-0.10 | $0.02 | $0.04 | $0.01 |
Total Assets | $162.01M | $166.13M | $159.38M | $152.65M |
Total Liabilities | $25.03M | $23.85M | $21.97M | $23.20M |
Cash & Equivalents | $37.50M | $37.07M | $40.40M | $36.49M |
Free Cash Flow OCF − CapEx | $3.00M | $-180.00K | $5.59M | $1.58M |
Shares Outstanding | 91.34M | 91.31M | 90.89M | 90.82M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.